-

$undefined

N/A

(N/A)

Actuate Therapeutics :ACTU Actuate is a clinical-stage biopharmaceutical company dedicated to developing [cutting-edge] therapies for cancers with high unmet needs. The company’s product candidate, elraglusib is a small molecule GSK-3 inhibitor designed to restore balance in the NF-κB pathway, effectively reducing inflammation, chemoresistance, and tumor progression. Elraglusib injection is being developed as a potential monotherapy and as part of combination therapy in pancreatic cancer and Ewing sarcoma, while elraglusib oral tablet is being developed in solid cancers. The U.S. Food and Drug Administration (FDA) has granted elraglusib Fast Track and Orphan Drug designations for the treatment of pancreatic cancer.

Location: Fort Worth, Texas, United States | Industry: https://actuatetherapeutics.com/ | Sector:

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

184.7M

Cash

8.642M

Avg Qtr Burn

-5.461M

Short % of Float

2.19%

Insider Ownership

19.03%

Institutional Own.

52.29%

Qtr Updated

12/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Elraglusib Details Advanced Salivary Gland Carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elraglusib Details Metastatic pancreatic ductal adenocarcinoma (mPDAC)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.